Study design (if review, criteria of inclusion for studies)
double-blind, placebo-controlled study
Participants
10 patients with CF who were more than 18 years old
Interventions
inhaled ipratropium bromide and metaproterenol as bronchodilators.
Outcome measures
efficacy
Main results
The mean FEV1 of the group improved 17.1 percent after treatment with ipratropium bromide, 12.5 percent after metaproterenol treatment, and 16.6 percent after treatment with both of these medications together. There was no significant difference between these responses and patients who responded to one treatment tended to respond to the other. The side effects with these medications were minimal.
Authors' conclusions
When compared with patients in previous studies, our patients, who were much older as a group, demonstrated a greater degree of bronchodilation with ipratropium bromide and metaproterenol, as well as a greater degree of bronchoconstriction with placebo.